1Jacobsson LT, Axell TE, Hansen BU, et al. Dry eyes or mouth: an epidemiological study in Sweden adults, with special reference to primary Sjogren's syndrome [ J ]. J Autoimmun,1989, 2(4): 521-524.
4Kok MR, Yamano S, Lodde BM, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome [ J ]. Hum Gene Ther, 2003, 14 (17) :1605-1618.
5Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren 's Syndrome (TRIPSS) [ J ]. Arthritis Rheum,2004,50(4) : 1270-1276.
6Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study [ J]. Arthritis Rheum,2005,52(9) : 2740-2750.
7Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland im- munohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma [ J ]. Ann Rheum Dis,2005,64(6) :958-960.
8Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody ) in primary Sjogren's syndrome: an open-label phase I / II study [ J ]. Arthritis Res Ther,2006,8(4) : R129.
